879009-95-7

Upstream product

• 34294-79-6 (S)-(-)-3-aminopiperidin-2-one 
• 3184-13-2 L-ornithine hydrochloride 
• 234082-35-0 methyl 3-chloro-4-fluorobenzoate 
• 54012-73-6 (S)-piperidin-3-amine 

Downstream Products

• 334618-62-1 methyl 3-chloro-4-{(3S)-(pyrimidin-2-ylamino)piperidin-1-yl}benzoate 
• 334618-67-6 (S)-2-Benzenesulfonylamino-3-{3-chloro-4-[(S)-3-(pyrimidin-2-ylamino)-piperidin-1-yl]-benzoylamino}-propionic acid tert-butyl ester 
• 334618-65-4 3-chloro-4-{(3S)-(pyrimidin-2-ylamino)piperidin-1-yl}benzoic acid 

Relevant academic research and scientific papers

Tricyclic pharmacophore-based molecules as novel integrin αvβ3 antagonists. Part III: Synthesis of potent antagonists with αvβ3/α IIbβ3 dual activity and improved water solubility

In order to optimize our novel integrin αvβ 3/αIIbβ3 dual antagonists, spatial screening at the N-terminus was performed. The αvβ 3 antagonistic activity varied depending on the space that was occupied by the N-terminus, but high potency against αIIbβ 3 was well maintained. The (3S)-aminopiperidine analogue had the strongest activity against αvβ3, and the S isomer at piperidine was more potent than the R isomer. Compounds selected on the basis of SAR analysis of a novel lead compound showed acceptable early absorption, distribution, metabolism, excretion, and toxicity (ADMET) profiles and sufficient water solubility for use as infusion drugs. Docking studies with the αvβ3 receptor were performed to confirm the SAR findings.